Regulatory Milestones

Amgen Inc. (NASDAQ:AMGN) lost $0.26 to $52.08 last week after partner Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) submitted an MAA for denosumab (AMG 162) in Japan to treat bone disorders stemming from bone metastases. Daiichi Sankyo has Japanese rights to the human mAb targeting receptor activator of NF-kappa B ligand (RANKL; TNFSF11).

Celgene Corp. (NASDAQ:CELG) lost $1.83 to $51.84 last week after the U.K.'s NICE issued a final appraisal determination that recommended the use of thalidomide for first-line treatment of multiple myeloma (MM) in combination with an alkylating agent and a corticosteroid in patients for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate (see Online Links, A18)...